Influence of leukotriene pathway polymorphisms on response to montelukast in asthma

John J. Lima, Shu Zhang, Audrey Grant, Lianhe Shao, Kelan G. Tantisira, Hooman Allayee, Jianwei Wang, James Sylvester, Janet Teresa Holbrook, Robert A Wise, Scott T. Weiss, Kathleen Barnes

Research output: Contribution to journalArticle

Abstract

Rationale: Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. Objective: To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. Methods: Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, χ2 and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. Measurements: Outcomes were asthma exacerbation rate and changes in FEV1 compared with baseline. Results: DNA was collected from 252 participants: 69% were white, 26% were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV1 (p <0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. Conclusions: Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.

Original languageEnglish (US)
Pages (from-to)379-385
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume173
Issue number4
DOIs
StatePublished - Feb 15 2006
Externally publishedYes

Fingerprint

montelukast
Leukotrienes
Single Nucleotide Polymorphism
Asthma
Genes
Haplotypes
Logistic Models
Genotype
Linkage Disequilibrium
Gene Frequency
African Americans
Mass Spectrometry
Analysis of Variance

Keywords

  • Antiinflammatory
  • Montelukast
  • Pharmacodynamic
  • Pharmacogenetic

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. / Lima, John J.; Zhang, Shu; Grant, Audrey; Shao, Lianhe; Tantisira, Kelan G.; Allayee, Hooman; Wang, Jianwei; Sylvester, James; Holbrook, Janet Teresa; Wise, Robert A; Weiss, Scott T.; Barnes, Kathleen.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 173, No. 4, 15.02.2006, p. 379-385.

Research output: Contribution to journalArticle

Lima, JJ, Zhang, S, Grant, A, Shao, L, Tantisira, KG, Allayee, H, Wang, J, Sylvester, J, Holbrook, JT, Wise, RA, Weiss, ST & Barnes, K 2006, 'Influence of leukotriene pathway polymorphisms on response to montelukast in asthma', American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 4, pp. 379-385. https://doi.org/10.1164/rccm.200509-1412OC
Lima, John J. ; Zhang, Shu ; Grant, Audrey ; Shao, Lianhe ; Tantisira, Kelan G. ; Allayee, Hooman ; Wang, Jianwei ; Sylvester, James ; Holbrook, Janet Teresa ; Wise, Robert A ; Weiss, Scott T. ; Barnes, Kathleen. / Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. In: American Journal of Respiratory and Critical Care Medicine. 2006 ; Vol. 173, No. 4. pp. 379-385.
@article{25165de213b74dffaed3043777325a34,
title = "Influence of leukotriene pathway polymorphisms on response to montelukast in asthma",
abstract = "Rationale: Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. Objective: To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. Methods: Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, χ2 and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. Measurements: Outcomes were asthma exacerbation rate and changes in FEV1 compared with baseline. Results: DNA was collected from 252 participants: 69{\%} were white, 26{\%} were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV1 (p <0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. Conclusions: Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.",
keywords = "Antiinflammatory, Montelukast, Pharmacodynamic, Pharmacogenetic",
author = "Lima, {John J.} and Shu Zhang and Audrey Grant and Lianhe Shao and Tantisira, {Kelan G.} and Hooman Allayee and Jianwei Wang and James Sylvester and Holbrook, {Janet Teresa} and Wise, {Robert A} and Weiss, {Scott T.} and Kathleen Barnes",
year = "2006",
month = "2",
day = "15",
doi = "10.1164/rccm.200509-1412OC",
language = "English (US)",
volume = "173",
pages = "379--385",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "4",

}

TY - JOUR

T1 - Influence of leukotriene pathway polymorphisms on response to montelukast in asthma

AU - Lima, John J.

AU - Zhang, Shu

AU - Grant, Audrey

AU - Shao, Lianhe

AU - Tantisira, Kelan G.

AU - Allayee, Hooman

AU - Wang, Jianwei

AU - Sylvester, James

AU - Holbrook, Janet Teresa

AU - Wise, Robert A

AU - Weiss, Scott T.

AU - Barnes, Kathleen

PY - 2006/2/15

Y1 - 2006/2/15

N2 - Rationale: Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. Objective: To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. Methods: Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, χ2 and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. Measurements: Outcomes were asthma exacerbation rate and changes in FEV1 compared with baseline. Results: DNA was collected from 252 participants: 69% were white, 26% were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV1 (p <0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. Conclusions: Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.

AB - Rationale: Interpatient variability in montelukast response may be related to variation in leukotriene pathway candidate genes. Objective: To determine associations between polymorphisms in leukotriene pathway candidate genes with outcomes in patients with asthma receiving montelukast for 6 mo who participated in a clinical trial. Methods: Polymorphisms were typed using Sequenom matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass array spectrometry and published methods; haplotypes were imputed using single nucleotide polymorphism-expectation maximization (SNP-EM). Analysis of variance and logistic regression models were used to test for changes in outcomes by genotype. In addition, χ2 and likelihood ratio tests were used to test for differences between groups. Case-control comparisons were analyzed using the SNP-EM Omnibus likelihood ratio test. Measurements: Outcomes were asthma exacerbation rate and changes in FEV1 compared with baseline. Results: DNA was collected from 252 participants: 69% were white, 26% were African American. Twenty-eight SNPs in the ALOX5, LTA4H, LTC4S, MRP1, and cysLT1R genes, and an ALOX5 repeat polymorphism were successfully typed. There were racial disparities in allele frequencies in 17 SNPs and in the repeat polymorphism. Association analyses were performed in 61 whites. Associations were found between genotypes of SNPs in the ALOX5 (rs2115819) and MRP1 (rs119774) genes and changes in FEV1 (p <0.05), and between two SNPs in LTC4S (rs730012) and in LTA4H (rs2660845) genes for exacerbation rates. Mutant ALOX5 repeat polymorphism was associated with decreased exacerbation rates. There was strong linkage disequilibrium between ALOX5 SNPs. Associations between ALOX5 haplotypes and risk of exacerbations were found. Conclusions: Genetic variation in leukotriene pathway candidate genes contributes to variability in montelukast response.

KW - Antiinflammatory

KW - Montelukast

KW - Pharmacodynamic

KW - Pharmacogenetic

UR - http://www.scopus.com/inward/record.url?scp=32444440309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32444440309&partnerID=8YFLogxK

U2 - 10.1164/rccm.200509-1412OC

DO - 10.1164/rccm.200509-1412OC

M3 - Article

C2 - 16293801

AN - SCOPUS:32444440309

VL - 173

SP - 379

EP - 385

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 4

ER -